Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.66 |
| ▸ | KDR | P35968 | 6/20 | 0.64 |
| ▸ | EPHB4 | P54760 | 5/20 | 0.64 |
| ▸ | EPHA2 | P29317 | 4/20 | 0.64 |
| ▸ | FBP1 | P09467 | 2/20 | 0.60 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.59 |
| ▸ | AURKA | O14965 | 1/20 | 0.59 |
| ▸ | INSR | P06213 | 1/20 | 0.59 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.59 |
| ▸ | FLT4 | P35916 | 1/20 | 0.59 |
| ▸ | CLK1 | P49759 | 1/20 | 0.59 |
| ▸ | TEK | Q02763 | 1/20 | 0.59 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.59 |
| ▸ | RAF1 | P04049 | 1/20 | 0.54 |
| ▸ | BRAF | P15056 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4219212 | 0.96 | EGFR (0.66) | EGFRKDREPHB4EPHA2FBP1 | |
| SCHEMBL5230552 | 0.96 | EGFR (0.68) | EGFRKDREPHB4EPHA2FBP1 | |
| SCHEMBL6989211 | 0.92 | EGFR (0.68) | EGFRKDREPHB4EPHA2FBP1 | |
| SCHEMBL1418424 | 0.87 | EGFR (0.66) | EGFRKDREPHB4EPHA2FBP1 | |
| SCHEMBL7226668 | 0.87 | KDR (0.68) | EGFRKDREPHB4EPHA2FBP1 | |
| SCHEMBL7226666 | 0.87 | KDR (0.68) | EGFRKDREPHB4EPHA2FBP1 | |
| SCHEMBL4225070 | 0.87 | EGFR (0.65) | EGFRKDREPHB4EPHA2FBP1 | |
| SCHEMBL5225676 | 0.86 | EGFR (0.74) | EGFRKDREPHB4EPHA2FBP1 | |
| SCHEMBL1418776 | 0.86 | KDR (0.66) | EGFRKDREPHB4EPHA2FBP1 | |
| SCHEMBL5228447 | 0.86 | EGFR (0.67) | EGFRKDREPHB4EPHA2FBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1315718-B1 | BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE, AND METHODS FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM PHARMA (DE) | 2007-11-28 | — | — | EP | disclosed |
| US-6656946-B2 | For treating diseases, particularly tumoral diseases, diseases of the lungs and respiratory tract | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-12-02 | — | — | US | disclosed |
| US-6617329-B2 | Administering a therapeutically effective amount of aminoquinozoline compound to treat benign or malignant tumour, a disease of the respiratory tract or lungs, polyps, kidney or skin disease and a disease of gastrointestinal tract | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-09-09 | — | — | US | disclosed |
| EP-1315718-A1 | BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE, AND METHODS FOR THE PRODUCTION THEREOF | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2003-06-04 | — | — | EP | disclosed |
| EP-1315705-A1 | BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE, AND METHODS FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM ZENTRALE GMBH (DE) | 2003-06-04 | — | — | EP | disclosed |
| US-20020082271-A1 | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-06-27 | — | — | US | disclosed |
| US-20020049197-A1 | Aminoquinazolines and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-04-25 | — | — | US | disclosed |
| WO-2002018372-A1 | BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE, AND METHODS FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-03-07 | — | — | WO | disclosed |
| WO-2002018351-A1 | BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE, AND METHODS FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049197-A1 | Aminoquinazolines and their use as medicaments | JAK1, ABL1, JAK2 | EGFR 246/4885KDR 717/4885EPHB4 3011/4885 |
| US-20020082271-A1 | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases | MAP3K1, MAP3K19, MAP3K20 | EGFR 137/4885KDR 500/4885EPHB4 1814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.